ARS Pharmaceuticals, Inc.
SPRY
$9.86
$0.313.25%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,471.62% | 3,043.40% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,471.62% | 3,043.40% | -- | -- | -- |
| Cost of Revenue | 141.28% | 30.79% | -22.70% | 14.34% | 51.07% |
| Gross Profit | 973.90% | 204.72% | 175.03% | 2,529.17% | 17.82% |
| SG&A Expenses | 287.69% | 507.25% | 416.51% | 420.26% | 28.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 259.81% | 299.82% | 242.25% | 285.14% | 32.47% |
| Operating Income | -144.58% | -210.39% | -181.81% | 561.54% | -20.97% |
| Income Before Tax | -167.41% | -258.60% | -229.77% | 800.64% | -28.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -167.41% | -258.60% | -229.77% | 796.62% | -28.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -167.41% | -258.60% | -229.77% | 796.62% | -28.67% |
| EBIT | -144.58% | -210.39% | -181.81% | 561.54% | -20.97% |
| EBITDA | -143.02% | -208.93% | -179.93% | 562.37% | -20.99% |
| EPS Basic | -162.66% | -252.90% | -224.37% | 787.27% | -26.75% |
| Normalized Basic EPS | -162.66% | -252.97% | -187.80% | 640.48% | -26.75% |
| EPS Diluted | -162.66% | -252.90% | -224.37% | 663.67% | -26.75% |
| Normalized Diluted EPS | -162.66% | -252.97% | -187.80% | 541.52% | -26.75% |
| Average Basic Shares Outstanding | 1.83% | 1.58% | 1.63% | 1.32% | 1.52% |
| Average Diluted Shares Outstanding | 1.83% | 1.58% | 1.63% | 24.01% | 1.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |